Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist-Related Facial Aging

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for obesity and type 2 diabetes, resulting in rapid or massive weight loss (MWL) that can profoundly affect facial adipose tissue (AT) and skin homeostasis. Facial AT, comprising dermal, subcutaneous, and deep layers, plays a critical role in structural support, extracellular matrix (ECM) maintenance, and paracrine signaling to fibroblasts and keratinocytes. GLP-1 RA-MWL leads to AT depletion, with associated skin laxity, volume loss, and accelerated aging, particularly in periorbital and midfacial regions. Concurrently, improved glycemic control reduces advanced glycation end products, dampens inflammation, and preserves collagen integrity, highlighting the complex effects on the cutaneous microenvironment.

To develop a regenerative, multifaceted approach for optimal aesthetic management.

Our proposed protocol includes multilayer fat grafting (millifat, microfat, nanofat) to restore AT and support fibroblast function, scaffolds such as calcium hydroxyapatite and poly-L-lactic acid to stimulate collagen and adipogenesis, hybrid hyaluronic acid complexes for volumization, and energy-based devices including microfocused ultrasound and fractional lasers to enhance ECM remodeling and skin tightening. Adjunctive biochemical cues such as polynucleotides, peptides, and platelet-rich plasma further promote tissue regeneration.

A staged, individualized treatment plan, combined with lifestyle and nutritional optimization, ensures sustainable aesthetic outcomes for patients experiencing GLP-1 RA-associated facial changes.